About this episode
在肿瘤治疗领域，肿瘤浸润淋巴细胞（TIL）疗法是被很多专家看好的一种颠覆性技术。2024年美国食品药品监督管理局批准上市了全球首款TIL药物，也是全球首个获批用于实体瘤的 T 细胞疗法，标志着实体瘤治疗有了新式“武器”。
Get every episode summarized
Each time 天方烨谈 publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
